Source:http://linkedlifedata.com/resource/pubmed/id/16450289
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-2-1
|
pubmed:abstractText |
We investigated the plasma glucose-lowering mechanism(s) of Rh2, a ginsenoside derived from Panax ginseng, in rats with streptozotocin-induced diabetes (STZ-diabetic rats). After intravenous injection over 120 min into fasting STZ-diabetic rats, Rh2 decreased plasma glucose in a dose-dependent manner. In parallel to the lowering of plasma glucose, an increase of plasma beta-endorphin-like immunoreactivity was observed. In addition, naloxone and naloxonazine at doses sufficient to block opioid mu-receptors inhibited the plasma glucose-lowering action of Rh2 in genetically wild-type, diabetic mice. In contrast, Rh2 failed to lower plasma glucose in opioid mu-receptor knockout diabetic mice. An increase in gene expression at both the mRNA and protein levels of glucose transporter subtype 4 (GLUT 4) was observed in soleus muscle obtained from STZ-diabetic rats treated with Rh2 three times daily for one day; this increase in expression was absent when opioid mu-receptors were blocked. In conclusion, our results suggest that ginsenoside Rh2 may lower plasma glucose in STZ-diabetic rats based on an increase in beta-endorphin secretion that activates opioid mu-receptors thereby resulting in an increased expression of GLUT 4.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Ginsenosides,
http://linkedlifedata.com/resource/pubmed/chemical/Glucose Transporter Type 4,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, mu,
http://linkedlifedata.com/resource/pubmed/chemical/Streptozocin,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Endorphin,
http://linkedlifedata.com/resource/pubmed/chemical/ginsenoside Rh2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0032-0943
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
72
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9-13
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16450289-Animals,
pubmed-meshheading:16450289-Blood Glucose,
pubmed-meshheading:16450289-Diabetes Mellitus, Experimental,
pubmed-meshheading:16450289-Ginsenosides,
pubmed-meshheading:16450289-Glucose Transporter Type 4,
pubmed-meshheading:16450289-Male,
pubmed-meshheading:16450289-Mice,
pubmed-meshheading:16450289-Panax,
pubmed-meshheading:16450289-Phytotherapy,
pubmed-meshheading:16450289-Rats,
pubmed-meshheading:16450289-Rats, Wistar,
pubmed-meshheading:16450289-Receptors, Opioid, mu,
pubmed-meshheading:16450289-Streptozocin,
pubmed-meshheading:16450289-beta-Endorphin
|
pubmed:year |
2006
|
pubmed:articleTitle |
Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats.
|
pubmed:affiliation |
Neurosurgical Division, Department of Surgery, National Taiwan University Hospital, Taipei City, Taiwan, R.O.C.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|